Glykopyrroniumbromid Accord (Glycopyrronium Bromide)

Glykopyrroniumbromid Accord is an injectable solution containing the anticholinergic agent glycopyrronium bromide. It is supplied in a sterile formulation for intramuscular or intravenous administration and is marketed in the European Union as a prescription‑only medication. Glycopyrronium bromide acts as a competitive muscarinic receptor antagonist, reducing secretions and producing bronchodilation. The product is used in peri‑operative settings and for certain respiratory conditions and chronic obstructive pulmonary disease (COPD) management.

Glykopyrroniumbromid Accord is indicated for several clinical situations where reduction of secretions or bronchodilation is desired.

- Pre‑operative reduction of salivary, respiratory and gastric secretions to facilitate anesthesia. - Adjunct therapy for chronic obstructive pulmonary disease (COPD) to improve airflow. - Management of acute bronchospasm in asthma when other bronchodilators are insufficient. - Control of excessive airway secretions during mechanical ventilation. - Use as an antisecretory agent in patients with excessive oral or bronchial secretions.

The safety profile of glycopyrronium bromide reflects its anticholinergic activity and includes both frequent and rare adverse events.

Common: - Dry mouth (xerostomia) or reduced salivation. - Throat irritation, hoarseness or dysphagia. - Mild constipation or decreased gastrointestinal motility. - Transient increase in heart rate (tachycardia) without other cardiac symptoms. - Blurred vision or difficulty focusing due to pupil dilation. - Nausea or mild abdominal discomfort.

Serious: - Severe bronchospasm or paradoxical airway narrowing requiring emergency intervention. - Acute urinary retention leading to painful bladder distension. - Allergic reactions including rash, angioedema, bronchial edema or anaphylaxis. - Cardiac arrhythmias such as atrial fibrillation or ventricular ectopy. - Marked hypotension or shock secondary to excessive anticholinergic effect.

When prescribing Glykopyrroniumbromid Accord, clinicians should evaluate patient‑specific factors and monitor for conditions that may be worsened by anticholinergic activity.

- Use caution in patients with glaucoma, especially narrow‑angle type. - Avoid in individuals with known urinary outflow obstruction or severe prostatic hypertrophy. - Assess cardiac history; tachyarrhythmias may be exacerbated. - Consider dose adjustment or close monitoring in the elderly or those with renal impairment. - Do not administer to patients with known hypersensitivity to glycopyrronium bromide or formulation excipients. - Evaluate pregnancy status; safety data are limited.

Glycopyrronium bromide can modify the pharmacodynamic or pharmacokinetic profile of several medicines; awareness of these interactions helps prevent adverse outcomes.

Avoid: - Concurrent use with other anticholinergic agents (e.g., atropine, ipratropium) may increase anticholinergic burden. - Co‑administration with potent cholinesterase inhibitors (e.g., neostigmine) may reduce therapeutic effect.

Use with caution: - Beta‑adrenergic bronchodilators (e.g., albuterol) – monitor for additive cardiovascular effects. - Cardiac glycosides (e.g., digoxin) – anticholinergic activity may alter heart rate control. - Anesthetic agents that depress respiration – observe for enhanced bronchial secretions control. - Diuretics – monitor electrolytes if significant fluid shifts occur.